The first patient has been enrolled in PROPEL, a multicenter registry evaluating Aliya® pulsed electric field (PEF) ablation ...

Cancer stem cells (CSCs) drive recurrence and resistance, evading standard therapies through iron-rich metabolism and ...

Researchers have identified RUNX1C, an RNA isoform that drives chemoresistance in acute myeloid leukemia (AML). The study, ...

The FDA has granted accelerated approval to Wegovy® (semaglutide) as the first treatment for MASH with moderate-to-advanced ...

A first-in-human phase 1 trial of the Fc-enhanced CD40 agonist antibody 2141-V11 has shown striking results: six of 12 ...

Researchers have developed a novel cancer therapy using Salmonella typhimurium to deliver an oncolytic virus directly into ...

FDA approved Papzimeos (zopapogene imadenovec), the first-in-class, non-replicating adenoviral vector-based immunotherapy, ...

A novel mRNA-based vaccine encoding tumor-specific neoantigens significantly enhanced anti-PD-1 therapy in gastric cancer ...

New findings, published in Cellular and Molecular Gastroenterology and Hepatology, show that the transcription factor CREB ...

The FDA has granted accelerated approval to zongertinib for pretreated, HER2+ non-squamous NSC lung cancer, based on results ...

The FDA has granted accelerated approval to Modeyso™ (dordaviprone) as the first treatment for recurrent H3 K27M-mutant ...

Birelentinib has received FDA Fast Track Designation for relapsed/refractory chronic lymphocytic leukemia (CLL) or small ...